Kenneth B Ain

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi request reprint Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas
    Kenneth B Ain
    Thyroid Cancer Research Laboratory, Veterans Affairs Medical Center, Lexington, Kentucky, USA
    Thyroid 17:663-70. 2007
  2. ncbi request reprint Thyroglobulin: a specific serum marker for the management of thyroid carcinoma
    Ronald J Whitley
    Department of Pathology and Laboratory Medicine, 800 Rose Street, University of Kentucky, Lexington, KY 40536 02963, USA
    Clin Lab Med 24:29-47. 2004
  3. ncbi request reprint Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro
    Joshua M Dziba
    Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky 40511, USA
    J Clin Endocrinol Metab 89:2127-35. 2004
  4. ncbi request reprint Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors
    Joshua M Dziba
    Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky, USA
    Thyroid 12:1063-70. 2002
  5. ncbi request reprint Pathobiology of antineoplastic therapy in undifferentiated thyroid cancer
    Kenneth B Ain
    Thyroid Oncology Program, Division of Hematology and Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA
    Cancer Treat Res 122:357-67. 2004
  6. ncbi request reprint Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor
    Wei Li
    Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky 40511, USA
    J Clin Endocrinol Metab 92:1080-7. 2007
  7. ncbi request reprint High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
    Xiulong Xu
    Department of General Surgery, Rush Presbyterian St Luke s Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA
    Cancer Res 63:4561-7. 2003
  8. ncbi request reprint Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis
    Xiulong Xu
    Department of General Surgery, Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 9:5968-79. 2003
  9. ncbi request reprint Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    J Clin Endocrinol Metab 91:4013-21. 2006
  10. ncbi request reprint Outcomes of patients with differentiated thyroid carcinoma following initial therapy
    Jacqueline Jonklaas
    Georgetown University Medical Center, Washington, DC 20007, USA
    Thyroid 16:1229-42. 2006

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas
    Kenneth B Ain
    Thyroid Cancer Research Laboratory, Veterans Affairs Medical Center, Lexington, Kentucky, USA
    Thyroid 17:663-70. 2007
    ..Objective: Since thyroid carcinomas are hypervascular and thalidomide is antiangiogenic, we assessed thalidomide's tumoristatic effects and toxicity in a phase II trial...
  2. ncbi request reprint Thyroglobulin: a specific serum marker for the management of thyroid carcinoma
    Ronald J Whitley
    Department of Pathology and Laboratory Medicine, 800 Rose Street, University of Kentucky, Lexington, KY 40536 02963, USA
    Clin Lab Med 24:29-47. 2004
    ..Thyroglobulin measurements are a critical component of a multifaceted diagnostic approach to this disease...
  3. ncbi request reprint Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro
    Joshua M Dziba
    Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky 40511, USA
    J Clin Endocrinol Metab 89:2127-35. 2004
    ..We conclude that imatinib mesylate monotherapy would not be effective in ATC patients. Current preclinical data do not warrant future clinical studies of imatinib monotherapy for ATC...
  4. ncbi request reprint Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors
    Joshua M Dziba
    Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky, USA
    Thyroid 12:1063-70. 2002
    ..These results suggest that antitumoral effects of CA4P can be consequent to a combination of primary antineoplastic effects as well as the potential destruction of tumor vasculature...
  5. ncbi request reprint Pathobiology of antineoplastic therapy in undifferentiated thyroid cancer
    Kenneth B Ain
    Thyroid Oncology Program, Division of Hematology and Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA
    Cancer Treat Res 122:357-67. 2004
  6. ncbi request reprint Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor
    Wei Li
    Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky 40511, USA
    J Clin Endocrinol Metab 92:1080-7. 2007
    ..Dedifferentiated cells lose radioiodine uptake from human sodium-iodide symporter (hNIS) gene transcription failure consequent to genomic structure (chromatin compaction) and composition (CpG methylation)...
  7. ncbi request reprint High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
    Xiulong Xu
    Department of General Surgery, Rush Presbyterian St Luke s Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA
    Cancer Res 63:4561-7. 2003
    ..These observations suggest that mutated BRAF gene may cooperate with RET/PTC to induce the oncogenesis of PTC...
  8. ncbi request reprint Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis
    Xiulong Xu
    Department of General Surgery, Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 9:5968-79. 2003
    ..The purpose of this study was to evaluate HPR1 expression in thyroid neoplasms and its effect in degrading the HSPG substrates in the ECM and BM and to determine its role in thyroid tumor metastasis...
  9. ncbi request reprint Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    J Clin Endocrinol Metab 91:4013-21. 2006
    ..NF-kappaB has been implicated in the pathophysiology of the most aggressive forms of thyroid carcinoma, i.e. medullary and anaplastic...
  10. ncbi request reprint Outcomes of patients with differentiated thyroid carcinoma following initial therapy
    Jacqueline Jonklaas
    Georgetown University Medical Center, Washington, DC 20007, USA
    Thyroid 16:1229-42. 2006
    ..We were unable to show any impact, positive or negative, of specific therapies in stage I patients...
  11. pmc Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin
    Andrzej Slominski
    Departments of Pathology, and Surgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA
    J Invest Dermatol 119:1449-55. 2002
    ..We conclude that the expanding list of neuroendocrine elements expressed in the skin supports a strong role for this system in cutaneous biology...